Close Menu

data mining

Functional genomics firm The DNA Company acquired digital therapeutics app My Pain Sensei, giving it an AI development platform and a Health Canada medical device license.

The informatics firm is working on an RUO COVID-19 susceptibility risk score to inform researchers and policymakers itching to restart the US economy.

Mount Sinai bioinformaticians have quickly pivoted from Lyme disease research to building a reference tool for researchers pursuing COVID therapies. 

The Cold Spring Harbor Laboratory spinout will build predictive models for lung cancer progression and risk using its SpliceCore software platform.

Big Blue's IBM Research and Watson divisions are teaming with several national consortia to unlock and share molecular and clinical coronavirus data on HPC platforms.

The new NferX platform applies AI to single-cell RNA-seq and clinical data to help pinpoint coronavirus transmission and receptor pathways. 

The health system said that the program is encouraging patient compliance and increasing revenues and savings.

The multi-omics analytics company is assisting drug discovery and precision medicine as the first partner of Mayo's Clinical Data Analytics Platform.

The Scottish bioinformatics firm will crunch multi-omic datasets to assist Charles River Laboratories in "data-driven" drug discovery.

The Mayo Clinic Platform, now headed by John Halamka, will lean on Nference for multi-omics analytics to inform biomedical R&D and postmarketing surveillance.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.